


THE FDA MIGHT HAVE INADVERTENTLY IMPLANTED ESTABLISHMENT LABS AS THE NEXT HOT MEDTECH STOCK

May 7, 2019



RESEARCH SUMMARY

Establishment Labs (ESTA) has taken the breast implant industry by storm with its next level technology, 6th generation, Motiva Implants.

The reoperation rate is under 1% with a Motiva implant, no Motiva patient has gotten lymphoma, and the Motiva Ergonomix implants are a game changer.

A recent bearish report on ESTA discussed its related party transactions and an allegedly biased clinical study. But we conclude that these are not a big deal.

The FDA recently sent a warning letter about breast implant safety, which we believe will help ESTA because studies show its implants have a lower number of adverse events.

The breast implant industry is growing, and the growth rate could increase on a new perception of safety from Motiva implants.

Establishment Labs (ESTA) has taken the breast implant industry by storm with its next level technology, 6th generation, Motiva Implants.

The reoperation rate is under 1% with a Motiva implant, no Motiva patient has gotten lymphoma, and the Motiva Ergonomix implants are a game changer.

A recent bearish report on ESTA discussed its related party transactions and an allegedly biased clinical study. But we conclude that these are not a big deal.

The FDA recently sent a warning letter about breast implant safety, which we believe will help ESTA because studies show its implants have a lower number of adverse events.

The breast implant industry is growing, and the growth rate could increase on a new perception of safety from Motiva implants.

Read the whole article on Seeking Alpha [here](#).



Independent institutional-grade research focused on identifying asymmetric risks in small and micro-cap equities.

LEGAL DISCLAIMER

As of the publication date of our reports, White Diamond Research, along with its clients, affiliates, and related entities, may have a short position in the securities discussed and stand to realize significant gains in the event that the price of the stock declines. Use White Diamond Research at your own risk. You should do your own research and due diligence before making any investment decision. No information contained in our reports should be interpreted as financial advice.

© 2026 White Diamond Research LLC